Don't forget the royalty and milestones payments to Brickell, they're not insignificant, plus eps multiples after usually after tax.
On the other hand 10x is much too low a multiple for a pharma company, 30x imo is conservative, so in the end $8 isn't that unrealistic.
Also anticipating a fair amount of dilution to come to fund the marketing campaign but there's clearly so much fat here that it won't matter in the end.
Ann: Webinar Updated Commercial Research for Sofpironium Bromide, page-17
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
-0.010(2.41%) |
Mkt cap ! $734.6M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.5¢ | 39.5¢ | $3.680M | 8.989M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 297011 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 12027 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |